Although receptor tyrosine kinase inhibitors, such as imatinib or sunitinib, are therapeutically active antagonists of KIT and PDGFRA in KIT- or PDGFRA-mutated GIST[6-8], effective treatments for patients with advanced BRAF-mutant GIST have not been reported. Here, PDGFRA is linked to gastrointestinal stromal tumor.